Authors: Oyaizu, H Adachi, Y Okumura, T Okigaki, M Oyaizu, N Taketani, S Ikebukuro, K Fukuhara, S Ikehara, S

Citation: H. Oyaizu et al., Proteasome inhibitor 1 enhances paclitaxel-induced apoptosis in human lungadenocarcinoma cell line, ONCOL REP, 8(4), 2001, pp. 825-829

Authors: Mori, Y Matsubara, H Nose, A Shibasaki, Y Masaki, H Kosaki, A Okigaki, M Fujiyama, S Tanaka-Uchiyama, Y Hasegawa, T Iba, O Tateishi, E Amano, K Iwasaka, T

Citation: Y. Mori et al., Safety and availability of doxazosin in treating hypertensive patients with chronic renal failure, HYPERTENS R, 24(4), 2001, pp. 359-363

Authors: Andreev, J Galisteo, ML Kranenburg, O Logan, SK Chiu, ES Okigaki, M Cary, LA Moolenaar, WH Schlessinger, J

Citation: J. Andreev et al., Src and Pyk2 mediate G-protein-coupled receptor activation of epidermal growth factor receptor (EGFR) but are not required for coupling to the mitogen-activated protein (MAP) kinase signaling cascade, J BIOL CHEM, 276(23), 2001, pp. 20130-20135

Authors: Matsubara, H Shibasaki, Y Okigaki, M Mori, Y Masaki, H Kosaki, A Tsutsumi, Y Uchiyama, Y Fujiyama, S Nose, A Iba, O Tateishi, E Hasegawa, T Horiuchi, M Nahmias, C Iwasaka, T

Citation: H. Matsubara et al., Effect of angiotensin II type 2 receptor on tyrosine kinase Pyk2 and c-JunNH2-terminal kinase via SHP-1 tyrosine phosphatase activity: Evidence fromvascular-targeted transgenic mice of AT2 receptor, BIOC BIOP R, 282(5), 2001, pp. 1085-1091

Authors: Guinamard, R Okigaki, M Schlessinger, J Ravetch, JV

Citation: R. Guinamard et al., Absence of marginal zone B cells in Pyk-2-deficient mice defines their role in the humoral response, NAT IMMUNOL, 1(1), 2000, pp. 31-36

Authors: Harroch, S Palmeri, M Rosenbluth, J Custer, A Okigaki, M Shrager, P Blum, M Buxbaum, JD Schlessinger, J

Citation: S. Harroch et al., No obvious abnormality in mice deficient in receptor protein tyrosine phosphatase beta, MOL CELL B, 20(20), 2000, pp. 7706-7715